BLOG

Fierce-Biotech

Fresh from $316M raise, Sotio inks Merck deal for Keytruda combo trial

Sotio Biotech has advanced its effort to become a major player in the solid tumor space. Days after raising $316 million, Sotio has unveiled a deal with Merck to use Keytruda in a clinical trial that is central to its plans for investing in the megaround. 

Back to the Blog .st0{stroke:#000;stroke-width:3}.st0,.st1{fill:none}